{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:17:06Z","timestamp":1788239826876,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in microsatellite instability\u2013high (MSI-H) or mismatch repair\u2013deficient (dMMR) tumors. However, their role in dMMR serous ovarian cancer remains undefined, particularly when given without chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>We report the case of a 42-year-old woman with a strong family history of malignancy who presented with metastatic high-grade serous ovarian carcinoma involving the liver, peritoneum, lymph nodes, and bone. Tumor immunohistochemistry demonstrated isolated loss of MSH2 expression. Germline testing confirmed a pathogenic MSH2 mutation, establishing a diagnosis of Lynch syndrome. Following multidisciplinary discussion, combined chemoimmunotherapy was recommended; however, the patient declined cytotoxic chemotherapy and was treated with dual immune checkpoint blockade (ipilimumab and nivolumab). Early imaging demonstrated a rapid and marked metabolic response, with subsequent scans confirming near-complete resolution of disease. The patient underwent interval cytoreductive surgery, which revealed minimal residual disease. Maintenance nivolumab and bevacizumab were initiated postoperatively. At latest follow up after 2 years, the patient remains in complete radiologic remission, with no evidence of active disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the importance of comprehensive molecular profiling for patient selection and biomarker-guided treatment strategies in patients with Lynch syndrome. Despite the serous histology of the patient\u2019s ovarian cancer, the presence of dMMR by immunohistochemistry and an underlying history of Lynch syndrome supported the use of a chemotherapy-free regimen with dual ICIs. Subsequent somatic next-generation sequencing revealed MSI-H\/TMB-H disease, which explains the remarkable response that the patient had.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1868646","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:27:39Z","timestamp":1788236859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable response to dual immune checkpoint blockade in Lynch syndrome\u2013associated serous ovarian carcinoma: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Mohamad","family":"Mourad","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Assaf","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layal","family":"Al Mahmasani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Fakhruddin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer.","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1582464","DOI":"10.3389\/fimmu.2025.1582464","article-title":"Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types.","volume":"16","author":"Kondrateva","year":"2026","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41591-024-02942-7","article-title":"Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.","volume":"30","author":"Friedman","year":"2024","journal-title":"Nat Med"},{"key":"B9","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n          \n          2025"},{"key":"B10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.3390\/ijms23158726","article-title":"Microsatellite instability: from the implementation of the detection to a prognostic and predictive role in cancers.","volume":"23","author":"Amato","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.5306\/wjco.v15.i4.540","article-title":"Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status.","volume":"15","author":"Niu","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer.","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.","volume":"55","author":"Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1002\/cam4.2243","article-title":"Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras\/Raf pathway with TP53.","volume":"8","author":"Zhong","year":"2019","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial.","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer.","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.18632\/oncotarget.24770","article-title":"BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.","volume":"9","author":"Wieser","year":"2018","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1002\/ijc.33115","article-title":"Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.","volume":"147","author":"Salem","year":"2020","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cancergen.2024.12.002","article-title":"Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry.","author":"Yang","year":"2025","journal-title":"Cancer Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.3390\/cancers15204925","article-title":"DNA mismatch repair gene variant classification: evaluating the utility of somatic mutations and mismatch repair deficient colonic crypts and endometrial glands.","volume":"15","author":"Walker","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41379-018-0058-y","article-title":"Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.","volume":"31","author":"Pearlman","year":"2018","journal-title":"Mod Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2353\/jmoldx.2008.080031","article-title":"Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.","volume":"10","author":"Shia","year":"2008","journal-title":"J Mol Diagn"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/PAS.0000000000000298","article-title":"The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.","volume":"38","author":"Chui","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ygyno.2017.01.005","article-title":"Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.","volume":"144","author":"Ryan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trsl.2023.05.004","article-title":"Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes.","volume":"260","author":"H\u00e1jkov\u00e1","year":"2023","journal-title":"Transl Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41379-022-01109-4","article-title":"Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?","volume":"35","author":"Wang","year":"2022","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100992","DOI":"10.1016\/j.gore.2022.100992","article-title":"Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.","volume":"41","author":"Lam","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/jcpt.13364","article-title":"Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer.","volume":"46","author":"Ak","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.21873\/anticanres.16317","article-title":"Complete response to immune checkpoint inhibition in a platinum resistant primary ovarian cancer patient with Lynch syndrome: a case report and review of the literature.","volume":"43","author":"Chinczewski","year":"2023","journal-title":"Anticancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1534979","DOI":"10.3389\/fonc.2025.1534979","article-title":"Case report: successful treatment of a case of Lynch syndrome with double primary ovarian and rectal cancer.","volume":"15","author":"Yu","year":"2025","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e37149","DOI":"10.7759\/cureus.37149","article-title":"Ovarian carcinosarcoma and response to immunotherapy.","volume":"15","author":"Daniyal","year":"2023","journal-title":"Cureus."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:27:40Z","timestamp":1788236860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"alternative-id":["10.3389\/fmed.2026.1868646"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1868646","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1868646"}}